Reduction of proteinuria with angiotensin receptor blockers (Q37200557)

18 August 2017

1 reference

title

Reduction of proteinuria with angiotensin receptor blockers (English)

1 reference

18 August 2017

Jan Galle

1

1 reference

18 August 2017

1 July 2008

1 reference

Nature Clinical Practice Cardiovascular Medicine

18 August 2017

1 reference

18 August 2017

5 Suppl 1

1 reference

18 August 2017

S36-43

1 reference

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

21 January 2018

Leptin and renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

[Non-invasive screening for renovascular hypertension -- which test?]

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

The role of the endothelium in the control of vascular function

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

AMGEN International Prize: the history and future of renoprotection

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Standards of medical care for patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Telmisartan: a review of its use in the management of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0806

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0806

1 reference

18 August 2017

1 reference

PubMed ID

18580865